Recent research found 41% of pediatric patients with SLE are affected by at least mild disability, with higher pain scores correlating with increased disability. Mary Beth Son, MD, says determining how these children feel and what affects them daily is vital to “identifying targets we can hit as clinicians to improve their quality of life.”
Search results for: hospital
Results from Belimumab Safety Study
In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
Neutrophils & B Cells Create Unique Antibodies in Lupus Patients
NETs or LL37-DNA complexes may serve as future targets for SLE therapy. In a recent study, researchers identified a link between neutrophils and NETs, and the activation of self-reactive B cells. Their study describes a neutrophil-B cell interaction unique to lupus…
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…
Anticonvulsants Unhelpful for Low Back Pain
NEW YORK (Reuters Health)—Solid evidence suggests that anticonvulsants provide no benefit for low back or lumbar radicular pain and a high risk of harm, researchers say. “We started the study because these drugs were increasingly being used for low back pain and radiating leg pain, without the support of strong evidence of effectiveness,” principal investigator…
IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…
FDA Approves Baricitinib for RA Patients
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
Bringing Policy & Practice Together: A Conversation with GAC Member Ethan Craig, MD, MHS
In his clinic as a third-year fellow at Johns Hopkins Hospital in Baltimore, Ethan Craig, MD, MHS, says it’s not always easy to hear about patients struggling with step therapy or other barriers to treatment. However, as a member of the ACR’s Government Affairs Committee (GAC), he says his work to understand and improve policy…
ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program
On Sept. 23–25, the ACR will once again hold its annual Advocates for Arthritis fly-in event in Washington, D.C. Held in conjunction with the ACR’s Advocacy 101 course, the fly-in is a great way for members and their patients to learn about issues important to the practice of rheumatology and have the opportunity to actively…
ACR Responds to Drug Pricing Proposals
Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 318
- Next Page »